The analysis of the expression profiles of 12 neuroimmune-associated neuropeptide genes across tumor stages (Stages I–IV) revealed no significant differences in the expression levels of 11 genes (p > 0.05), although LYNX1 exhibited a significant downregulation in Stage I compared to later stages (p = 0.0142) (Figure 6). The gene discussed is LYNX1; the disease is neoplasm.